2024년 5월 28일 14:58

Oncocross and JW Pharmaceutical Team Up on AI-powered Drugs for Cancer and Regeneration

Oncocross, an AI biotech company specializing in drug discovery and development, announced that it has signed a joint research agreement with JW Pharmaceutical to develop new drugs based on the AI platform. Under this contract, the two companies w...

2023년 5월 11일 13:29

Oncocross Completes Phase 1 Global Clinical Trial of OC514, Treatment for Sarcopenia

Oncocross, a Seoul-based AI drug discovery and development biotech, announced the completion of phase 1 global clinical trial of OC514, a treatment targeting sarcopenia and other rare muscular diseases. Phase 1 was conducted in Australia. Sarcopen...

2022년 2월 28일 09:49

Oncocross Begins Phase I Clinical Trial of AI-Developed Drug for Sarcopenia

Oncocross, an AI-based drug development biotech, announced that it initiated a phase I global clinical trial for ‘OC514’ targeting muscular diseases including sarcopenia. Oncocross obtained Australia’s Therapeutic Goods Administration (“TGA”) appr...